On the XIX day of December, in the Year of Greatness MMXXV, the Emperor of Cost-Cutting proclaimed nine sacred pacts with the grand alchemists of the pharmaceutical guilds. Titans approached the throne — Amgen, Merck, Novartis, and others of similar magnitude — all bowing to the supreme doctrine known as Most-Favored-Nation Pricing, also called “Why were Americans paying more than everyone else?”

From this day forward, America pays what the rest of the civilized world pays — and often less, because we negotiate better. Drugs for diabetes, asthma, arthritis, multiple sclerosis, HIV, hepatitis, and even the dread emperor of illnesses, cancer, have been dragged down from their golden pedestals.

Where once patients received invoices resembling ancient scrolls, they now see numbers so small they can be read without magnifying glasses. HIV treatments priced like a casual dinner. Insulin for the cost of a respectable sandwich. Blood thinners cheaper than olive oil on sale.

But Trumpius Caesar does not stop at price cuts — he reclaims tribute. Foreign nations may no longer ride for free on American innovation. Billions earned abroad return home, redirected for the benefit of American patients. Innovation is no longer donated — it is repatriated.

Through TrumpRx, the imperial direct-to-patient marketplace, bloated list prices collapse like rotted amphitheater walls. No middlemen. No excuses. No bureaucratic priesthood chanting paperwork.

And because a strong empire plans ahead, the imperial vaults are filled: tons of vital pharmaceutical ingredients secured for emergencies, shortages, and storms yet to come. Asthma rescue compounds. Blood-thinning agents. Powerful antibiotics. Stockpiled. Secured. American.

Thus Trumpius Caesar fulfills a promise the establishment mocked and never dared to make:
America will no longer subsidize the world. The world will finally pay its share.